y*1
2 楼
Financial position:
Celsion ended December 31, 2014, with total cash and investments of $37.1
million. Management project that the current cash is enough to support
operating activities for the next two years.
Cash flows/expenses:
In 2014, Celsion used $21.4 million for operations, or approximately $1.8
million per month. Broken down, research and development costs increased to
$15 million versus $9.4 million in 2013, mainly due to initiation of the
OPTIMA study. General and administrative expenses grew to $8.9 million
compared to $6.5 million in 2013. For 2015, Celsion expects cash usage to be
around $2 million per month, which is reasonable given the increasing
enrollment in the OPTIMA study and further clinical development of the EGEN
assets.
Celsion ended December 31, 2014, with total cash and investments of $37.1
million. Management project that the current cash is enough to support
operating activities for the next two years.
Cash flows/expenses:
In 2014, Celsion used $21.4 million for operations, or approximately $1.8
million per month. Broken down, research and development costs increased to
$15 million versus $9.4 million in 2013, mainly due to initiation of the
OPTIMA study. General and administrative expenses grew to $8.9 million
compared to $6.5 million in 2013. For 2015, Celsion expects cash usage to be
around $2 million per month, which is reasonable given the increasing
enrollment in the OPTIMA study and further clinical development of the EGEN
assets.
y*1
3 楼
Thinly-traded nano cap Celsion (NASDAQ:CLSN) jumps 32% premarket on
robust volume in response to its announcement of positive interim results
from a Phase 2 study assessing ThermoDox in combination with mild
hyperthermia in patients with recurrent chest wall breast cancer, a type of
cancer highly resistant to treatment.
Out of the 16 enrolled patients, 12 were eligible for evaluation for
efficacy. Eight (67%) experienced a clinical benefit while seven (58%)
showed a local response, including five complete responses, two partial
responses and one with stable disease.
Enrollment should be completed in Q3.
ThermoDox is encapsulated doxorubicin. After infusion, it is heated to a
specific temperature which releases the cancer drug directly into a tumor.
robust volume in response to its announcement of positive interim results
from a Phase 2 study assessing ThermoDox in combination with mild
hyperthermia in patients with recurrent chest wall breast cancer, a type of
cancer highly resistant to treatment.
Out of the 16 enrolled patients, 12 were eligible for evaluation for
efficacy. Eight (67%) experienced a clinical benefit while seven (58%)
showed a local response, including five complete responses, two partial
responses and one with stable disease.
Enrollment should be completed in Q3.
ThermoDox is encapsulated doxorubicin. After infusion, it is heated to a
specific temperature which releases the cancer drug directly into a tumor.
相关阅读
bidu盘后追来得及吗？You ain't seen nothing yet随着百度，奇虎爆了请问 IB 的 Bill Payment 哪位用过贴一手歌，给明天受伤的人今天NASDAQ大的gap down是不是AMZN ER的原因？有没有股友用stockcharts.com Plan Pro的傻逼了。。。ZillowAMZN 320接了100股大盘怎么还不去2000点BTFD!!!有人收到Robinhood的邀请了吗？庄稼把AMZN的钱拿出来炒别的股票了把公司的President一般是干什么的？李克强与山东民工掰手指真受不了果子的rumor买Call短期策略跟风，发个年收入4万的生活 (转载)果果新高今天？今天哪只会爆？